Federation of Pharma Entrepreneurs (FOPE)’s Post

API manufacturing is facing unprecedented challenges and opportunities, from increasing regulatory scrutiny to rising costs and intensified competition, the industry is in a state of flux. Join the upcoming webinar with - Molly Bowman, Head of Strategy for Pharmaceutical SCM, Clarivate Analytics, Mike Ward, Head of Thought Leadership, Life Sciences, Clarivate Analytics, Alicia Xaka, Associate Director, Business Development, US & Canada, PROCOS S.P.A. (CBC Group) and Gunjan Singh, Head of Mature Markets API, Dr. Reddy's Laboratories - to explore the evolving landscape of API manufacturing, major industry changes in Chinese and Indian markets, navigating competitive pressures and more. Register here: https://lnkd.in/e-GBensb #RegulatoryCompliance #APIManufacturing #Pharma #Webinar #IndustryInsights

Are you attending CPHI in Milan this year? Don’t miss the upcoming webinar of Clarivate for Life Sciences & Healthcare! It’s a great opportunity to explore the latest trends, challenges, and opportunities in API manufacturing. #API #Manufacturing #CPHI #Milan #Clarivate

The changing dynamics of global API manufacturing - webinar imperdível para quem se preocupa com a cadeia de suprimentos global!

When R&D giants sneeze, clinical trials suffer. It’s a well-known fact that the #Pharma sector is among the most R&D intensive industries in the world, with massive investments in #Innovation. Based on quarterly reporting, however, we can see an overall drop in R&D spending between the first halves of 2023 and 2024 (with some companies hit harder than others). As a result, clinical trials are also declining, particularly in European countries. Key findings: - 🚨 12.9% global decrease in R&D spending - 🚨 Overall decline in all countries, including: -30.9% decrease in EU5 region  -22.9% decrease in Canada Reasons behind this decline in R&D go beyond cyclical investment trades. They also include more systemic issues, likely influenced by national policy decisions impacting the pharmaceutical sector. Countries and patients should take note of these issues to right the ship. #Research #ClinicalTrials #Pfizer #JnJ #Abbvie #Merck #Sanofi #Roche #GSK #AstraZeneca #Novartis #BMS Meir Pugatch Pugatch Consilium

When R&D giants sneeze, clinical trials suffer.  It’s a well-known fact that the #Pharma sector is among the most R&D intensive industries in the world, with massive investments in #Innovation. Based on quarterly reporting, however, we can see an overall drop in R&D spending between the first halves of 2023 and 2024 (with some companies hit harder than others). As a result, clinical trials are also declining, particularly in European countries.  Key findings: 🚨 12.9% global decrease in R&D spending 🚨 Overall decline in all countries, including: 30.9% decrease in EU5 region 22.9% decrease in Canada. Reasons behind this decline in R&D go beyond cyclical investment trades. They also include more systemic issues, likely influenced by national policy decisions impacting the pharmaceutical sector. Countries and patients should take note of these issues to right the ship.  #Research #ClinicalTrials #Pfizer #JnJ #Abbvie #Merck #Sanofi #Roche #GSK #AstraZeneca #Novartis #BMS Gabin Nathan

Ensuring that the #GPL creates competitive advantages through EU strengths was the driving message from the panel hosted by EuropaBio - the European Association for Bioindustries at #BIOEurope. Together with Wojciech Nowak, MA, EMBA (IMD) of Novartis, Fabrizio Conicella of Chiesi Group and Joao Incio, MD PhD of Biovance Capital, we looked towards a General Pharmaceutical Legislation that can enable disruptive and ambitious innovation. The discussion focused around EU key advantages, such as its depth of innovation through research and its drive towards rewarding sustainable product pipelines, however highlighted that you have to enable companies to reach those targets with balanced legislation. Innovators and their investors that drive novel therapies need manageable sustainability reporting so that they can focus on their strengths, together with predictable incentives to help them reach towards complex and unmet disease targets. The message to policy makers is to ensure the GPL amplifies strengths for a competitive EU position globally. The multiple components of he GPL must be considered together to ensure that they do not overwhelm the innovation engine and allow the EU's amazing strengths to shine.

With the recent crackdowns on Chinese companies, many industries have shifted away from working with them and towards alternative options. The electronic industry made the transition to Taiwan years ago, reaping numerous benefits. Should the pharmaceutical industry follow suit? If you're currently working with WuXi and seeking an alternative, let's talk! Check out this article on WuXi's role in the biopharma industry: https://lnkd.in/dHvtU6_k

Join Matthias Liefner, Jens Oelker, and Edward Locke in our upcoming Better Market Access webinar to discover how leading pharma companies are turning tender challenges into growth opportunities. Register now to gain insights into strategies for navigating complex procurement landscapes, building competitive differentiation, and leveraging tender excellence to drive sustainable success in an evolving market. skp.link/70we #BetterMarketAccess #Pharma #Biotech #TenderExcellence #SimonKucher

🧬 Pharma Now is giving you an exclusive chance to have your questions answered directly by the speakers at the #GlobalPharmaSupplyChain, organized by BrainLinx! 🎤 Meet our expert speakers: 👨💼 Faris Hattar, Associate Director, Hikma Pharmaceuticals 👨💼 Pablo Tovar Montaño, Economic & Social Affairs Team, EFPIA - European Federation of Pharmaceutical Industries and Associations 👨💼 Nico Höler, CEO & Co-Founder, Tec4med These industry leaders are ready to share their insights on the most pressing challenges and innovations in pharma supply. Now’s your opportunity to ask them directly! Drop your questions in the comments below, and get the expert insights. Don’t miss out on this exclusive chance to learn from the best in the business! 💬 #PharmaNow #AskTheExperts #GlobalPharmaSupplyChain #PharmaIndustry #SupplyChainExcellence #PharmaTrends #IndustryInsights